The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 6th 2024
The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Women's Health and Osteoporosis Studies That Should Be on Your Radar
November 20th 2020Over the course of this year there have been some pivotal studies on osteoporosis and women's health. We've published stories based on studies that explore the use of vitamin D and calcium supplementation and bone mineral density. We've featured a few studies that examine the effectiveness of bisphosphonates and the role of anabolic agents to to fight osteoporosis. Learn more about these and other studies in today's slideshow.
Treatment Sequence Matters in Osteoporosis
November 18th 2020Osteoporosis therapeutic treatments should always be individualized, says Felicia Cosman, M.D., an endocrinologist with Columbia University College of Physicians and Surgeons in New York. Dr. Cosman is the author of a study recently presented at the American College of Rheumatology annual meeting in which she shared results from a study that explored treatment sequences with romosozumab before or after antiresorptive medication.
More than 40% of Systemic Sclerosis Patients Have Osteoporosis and Osteopenia
November 18th 2020Diane Marr, rheumatology fellow at Stanford Healthcare and Clinics, recently presented a study at the annual meeting of the American College of Rheumatology in which she and her team examine the risk of osteopenia and osteoporosis in systemic sclerosis patients.
New Year May Bring New Lupus Treatments
November 13th 2020At this year's annual meeting of the American College of Rheumatology, there were a number of studies presented on different treatments for lupus. It's an exciting time in lupus research says Dr. Richard Furie, chief of rheumatology at Northwell Health in New York. In today's one on one interview, he breaks down some of the lupus studies presented at the meeting
ACR Set to Issue Updated Treatment Guidelines
November 12th 2020The American College of Rheumatology is expected to issue updated treatment guidelines for rheumatoid arthritis no later than spring 2021. The new guidelines will include recommended uses for biologics approved since the last update in 2015―including JAK inhibitors.
ACR Conference Roundup: New RA Treatment Guidelines Preview
November 12th 2020In this week's news roundup from Rheumatology Network, we highlight studies presented at the annual meeting of the American College of Rheumatology, which wrapped this week. Among the stories we covered included a preview of the soon-to-be released rheumatoid arthritis guidelines, promising new treatments for lupus nephritis and advances in osteoporosis care. Learn more in today's news roundup.
Q&A: Do glucocorticoids have a positive impact on bone?
November 12th 2020In this Q&A, Edgar Wiebe, M.D., of Charité University Medicine Berlin, discusses the findings of a study recently presented at the American College of Rheumatology annual meeting that looked at the impact of a number of factors on bone mineral density.
Medication Management Preferences Depend on Case Burden
November 12th 2020A survey of rheumatologists in the United States found that their prescriptions of medications such as NSAIDs, biologics and steroids during the COVID-19 pandemic is based on regional case burden rather than American College of Rheumatology guidance.
Q&A: Methotrexate and Tuberculosis
November 12th 2020Tuberculosis screening and ongoing clinical care is needed for patients prescribed methotrexate, particularly if co-administered with corticosteroids or other immunosuppressants, who live in areas where tuberculosis is common, according to researchers recently reporting at the annual meeting of the American College of Rheumatology.
In systemic sclerosis, which factors are linked to an increased risk of osteoporosis and fracture?
November 11th 2020Several factors can increase the risk of fractures and osteoporosis in patients with systemic sclerosis, including poor functional status and being underweight, according to researchers reporting at the annual meeting of the American College of Rheumatology on Saturday. However, the impact of proton pump inhibitors was less clear.
Long-Term Ixekizumab Versus Adalimumab in Psoriatic Arthritis
November 10th 2020In patients with psoriatic arthritis who are DMARD naïve, ixekizumab had similar efficacy at one year whether it was used as a monotherapy or in combination with methotrexate or csDMARD, while adalimumab showed better efficacy as a combination therapy.
DMARDs Increase Likelihood of Osteopenia and Osteoporosis in Scleroderma
November 10th 2020Non-corticosteroid immunosuppressant use and long duration of disease increase the likelihood of patients with systemic osteopenia being diagnosed with osteopenia and osteoporosis, according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.
Tofacitinib, Adalimumab, Methotrexate Show Similar Influenza Adverse Events in RA
November 10th 2020In a study that examined the influenza adverse events (AEs) of tofacitinib (Xeljanz, Pfizer) in patients with rheumatoid arthritis, similar AEs were seen with tofacitinib, adalimumab, methotrexate, and placebo, and between different tofacitinib doses and patient age groups, according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.
Q&A: Hydroxychloroquine and Heart Rhythm in SLE
November 10th 2020Patients with systemic lupus erythematous (SLE) who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals on electrocardiogram (EKG), even if they have chronic kidney disease (CKD), according to researchers reporting at the annual meeting of the American College of Rheumatology on Monday.
Rheumatic Disease Patients Bear the Brunt of Antimalarial Shortages
November 10th 2020Lessons learned from antimalarial drug shortages during the COVID-19 pandemic: rheumatic disease patients in African and South-East Asia had difficulty obtaining antimalarials as compared to counterparts in the Americas and Europe. Shortages led to worse mental and physical health outcomes. Antimalarials did not protect patients from COVID-19.
Awareness Campaign Increased DEXA Screenings for Osteoporosis
November 9th 2020Doctors increased their use of DEXA screening and initiate osteoporosis therapy more frequently after the implementation of an initiative to raise their awareness of the 2017 American College of Rheumatology (ACR) guidelines for the management of glucocorticoid-induced osteoporosis (GIOP), according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.
Corticosteroids Not a Contributor in Advanced Knee Osteoarthritis
November 9th 2020The use of corticosteroid injections may not be associated with the progression of knee osteoarthritis to the point of total knee replacement any more than the use of hyaluronic acid, according to a presentation made today at the American College of Rheumatology annual meeting.
Artificial Intelligence RA Study Shows a Five-Fold Increase in ACR70 Response
November 8th 2020In a study presented at the annual meeting of the American College of Rheumatology, UK researchers showcase a study in which artificial intelligence was successfully used to identify ACPA positivity and CRP of greater than 12.3 mg/L to identify rheumatoid arthritis patients more likely to respond to sarilumab.
Podcast: ACR Annual Meeting Preview
November 7th 2020Welcome to Overdrive, the podcast from Rheumatology Network. This week marks the start of the 2020 annual meeting of the American College of Rheumatology. Some of the studies we're covering include new therapies for lupus nephritis, the impact of COVID-19 on rheumatic disease patients, and pregnancy outcomes in ILD patients. Today, Dr. Fotios Koumpouras of the Yale School of Medicine, highlights some studies you won't want to miss at this year's meeting.
Abatacept for JIA Passes Long-term Safety Trial
November 7th 2020In a study that examined the long-term effectiveness of intravenous and subcutaneous abatacept (Orencia, Bristol-Myers Squibb) in patients with juvenile idiopathic arthritis (JIA), the treatment was safe and well-tolerated with no new safety risks identified, according to researchers reporting at the annual meeting of the American College of Rheumatology on Saturday.